Wire · opportunities
Kalshi to allow bets on clinical trials, FDA decisions
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
Prediction market platform Kalshi is launching markets on clinical trial outcomes and FDA decisions in partnership with AppliedXL, allowing investors to bet on individual drug approvals rather than entire company performance. The pilot restricts trading to late-stage trials with criteria defined before results are published, and includes bets on Gilead cancer drugs, Summit's lung cancer therapy, and AriBio's Alzheimer's candidate.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building trial forecasting, patient recruitment, or trial data analytics for biotech, you now have a market mechanism that prices your predictions in real time—and will expose which forecasters are actually right. The money moving into prediction markets on drug approvals is the earliest signal of which clinical endpoints matter to capital.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics